利拉鲁肽通过JAK2/STAT3信号通路影响糖尿病牙周炎的发生发展

Objective: to study the therapeutic effect of lillarutide on diabetic periodontitis in vitro and to explore its mechanism. Methods: human periodontal membrane cells were identified by inverted microscope, immunofluorescence and alizarin red staining. CCK-8 experiment screened the optimal drug concentration and time to establish the in vitro model of diabetic periodontitis. qRT-PCR and ELISA were used to detect the effect of liraglutide on IL-6 and TNF-α mRNA and protein in diabetic periodontitis model. qRT-PCR, ELISA and Western blot were used to investigate the mechanism of the effect of liraglutide on diabetic periodontitis. Results: human periodontal membrane cells were treated with 100 μg/mL AGEs and 1 μg/mL Pg-LPS for 24 h to establish an in vitro model of diabetic periodontitis. The expressions of IL-6, TNF-α, JAK2 and STAT3 were up-regulated in diabetic periodontitis model. JAK2, STAT3,IL-6 and TNF-α expression were upregulated after the addition of coumermycin A1 C-A1 (JAK2 agonist). Conclusion: Liraglutide has therapeutic effect on diabetic periodontitis by inhibiting JAK2 and STAT3 signaling pathways. Liraglutide is expected to be a new treatment for diabetic periodontitis.